MA46099A - Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial - Google Patents

Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial

Info

Publication number
MA46099A
MA46099A MA046099A MA46099A MA46099A MA 46099 A MA46099 A MA 46099A MA 046099 A MA046099 A MA 046099A MA 46099 A MA46099 A MA 46099A MA 46099 A MA46099 A MA 46099A
Authority
MA
Morocco
Prior art keywords
compounds
treatment
diseases associated
mitochondrial dysfunction
mitochondrial
Prior art date
Application number
MA046099A
Other languages
English (en)
French (fr)
Inventor
Antoine Danchin
Patrice Garnier
Agnieszka Sekowska
Original Assignee
Amabiotics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amabiotics filed Critical Amabiotics
Publication of MA46099A publication Critical patent/MA46099A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046099A 2016-08-30 2017-08-30 Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial MA46099A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16306094.0A EP3290039B1 (en) 2016-08-30 2016-08-30 Compounds for treating diseases associated with a mitochondrial dysfonction

Publications (1)

Publication Number Publication Date
MA46099A true MA46099A (fr) 2019-07-10

Family

ID=56896495

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046099A MA46099A (fr) 2016-08-30 2017-08-30 Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial

Country Status (15)

Country Link
US (2) US10857135B2 (enExample)
EP (2) EP3290039B1 (enExample)
JP (1) JP7065854B2 (enExample)
KR (1) KR20200011927A (enExample)
CN (1) CN110035758B (enExample)
AU (1) AU2017317651B2 (enExample)
BR (1) BR112019004236A2 (enExample)
CA (1) CA3034694A1 (enExample)
ES (1) ES2800917T3 (enExample)
MA (1) MA46099A (enExample)
MX (1) MX394782B (enExample)
RU (1) RU2019108824A (enExample)
SG (1) SG11201901689YA (enExample)
WO (1) WO2018041919A1 (enExample)
ZA (1) ZA201900997B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290039B1 (en) * 2016-08-30 2020-03-25 Amabiotics Compounds for treating diseases associated with a mitochondrial dysfonction
JP2021517124A (ja) * 2018-03-07 2021-07-15 エーエムエーバイオティクス アルツハイマー病を治療するための化合物
US20220096574A1 (en) * 2019-01-29 2022-03-31 Holobiome, Inc. Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis
EP4028014A1 (en) * 2019-09-12 2022-07-20 Stellate Therapeutics Compounds for treating neurodegenerative diseases
WO2021048431A1 (en) * 2019-09-12 2021-03-18 Amabiotics Compounds for treating ataxia
CN116850191A (zh) * 2023-06-16 2023-10-10 山东大学齐鲁医院 奎因在制备治疗线粒体功能障碍相关疾病药物中的应用
WO2026057085A1 (zh) * 2024-09-15 2026-03-19 澳门科技大学 Queuine在抗衰老中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936615A (ja) * 1982-08-24 1984-02-28 Takeda Chem Ind Ltd 発がん予防剤
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
JPH11506426A (ja) * 1995-04-25 1999-06-08 オリディグム コーポレイション 代謝経路のs−アデノシルメチオニン調節ならびに診断および治療におけるその使用
FR3002139B1 (fr) * 2013-02-21 2015-06-19 Amabiotics Utilisation cosmetique de la queuine
GB201417163D0 (en) * 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
EP3290039B1 (en) * 2016-08-30 2020-03-25 Amabiotics Compounds for treating diseases associated with a mitochondrial dysfonction

Also Published As

Publication number Publication date
BR112019004236A2 (pt) 2019-05-28
JP2019526634A (ja) 2019-09-19
EP3290039A1 (en) 2018-03-07
AU2017317651B2 (en) 2022-12-15
SG11201901689YA (en) 2019-03-28
US20210046056A1 (en) 2021-02-18
CN110035758A (zh) 2019-07-19
US10857135B2 (en) 2020-12-08
MX394782B (es) 2025-03-24
ZA201900997B (en) 2020-05-27
ES2800917T3 (es) 2021-01-05
US11684611B2 (en) 2023-06-27
RU2019108824A (ru) 2020-10-01
CA3034694A1 (en) 2018-03-08
MX2019002369A (es) 2019-11-07
JP7065854B2 (ja) 2022-05-12
KR20200011927A (ko) 2020-02-04
EP3506903A1 (en) 2019-07-10
EP3290039B1 (en) 2020-03-25
CN110035758B (zh) 2023-06-16
RU2019108824A3 (enExample) 2020-12-31
WO2018041919A1 (en) 2018-03-08
AU2017317651A1 (en) 2019-03-07
US20190224174A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
EP3448875A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) COMPOSITIONS FOR TREATING A DISEASE
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3370703A4 (en) GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES
MA49144A (fr) Polythérapies pour le traitement du cancer
MA45192A (fr) Traitement d'association
EP3340982A4 (en) COMPOUNDS FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISEASES
EP3452060A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
EP3411380A4 (en) CONNECTIONS FOR TREATING EYE DISORDERS OR DISEASES
EP3362065A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
MA41449A (fr) Polythérapies pour le traitement de cancers
MA50409A (fr) Polythérapies pour le traitement du cancer
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3463341A4 (en) AMINOACYLINDOL IMMUNOMODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP3352749A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
EP3630196A4 (en) COMBINATION THERAPIES FOR TREATMENT OF CANCER
EP3335041A4 (en) BIOMARKER FOR THE TREATMENT OF ALOPECIA AREATA
EP3328864A4 (en) THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND DRUG ABUSE
EP3419639A4 (en) AAV IDUA VECTOR FOR TREATING BLINDNESS IN CONNECTION WITH MPS I
EP3490561A4 (en) COMBINATIONS FOR TREATING CANCER
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
EP3416645A4 (en) COMPOUNDS FOR THE TREATMENT OF MALARIA
EP3866777A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP3316887A4 (en) GLS1-INHIBITOR TO TREAT DISEASES